Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07088159
NCT07088159AvailableNot Applicable

Intermediate-size Patient Population Expanded Access Protocol for Tazbentetol in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

Spinogenix28 sites in 1 countryStarted: July 28, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Available
Sponsor
Locations
28
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this Expanded Access Program is to provide tazbentetol to ALS patients who are not eligible to enroll in an ALS clinical trial. This Expanded Access Program will assess safety and tolerability, and clinical efficacy of tazbentelol.

Detailed Description

This is a multi-site, intermediate-size patient population expanded access protocol developed to provide compassionate use access to tazbentetol to adult patients with ALS who have progressed following available standard of care.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •ALS diagnosis
  • •Age 18 -85 years at time of signing informed consent form
  • •Ineligible for other interventional ALS clinical research participation
  • •Vital Capacity greater than 35% of predicted capacity for age, height, and sex
  • •If currently taking standard of care treatment for ALS, must be on stable dose for at least 30 days prior to taking tazbentetol.
  • •Life expectancy of at least 6 months, according to Investigator's judgement

Exclusion Criteria

  • •Clinically significant and/or unstable medical condition (other than ALS) that would pose a risk to the patient
  • •Known ongoing or clinically uncontrolled cardiac disease
  • •Clinically significant liver disease
  • •Clinical significant cognitive impairment or neurological disorder, as determined by Investigator judgement
  • •Concomitant use of another investigational medical product for treatment of ALS
  • •Unable to reliably and regularly swallow whole oral medications on a daily basis

Investigators

Sponsor
Spinogenix
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (28)

Loading locations...

Similar Trials

Temporarily Not Available
Not Applicable
INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITYSarcopeniaObesity and Obesity-related Medical Conditions
NCT06784297Immunis, Inc.
No Longer Available
Not Applicable
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)
NCT05086094Biohaven Pharmaceuticals, Inc.
Available
Not Applicable
Intermediate-Size Expanded Access Protocol (EAP) for LP352Dravet SyndromeLennox Gastaut SyndromeDevelopmental and Epileptic Encephalopathies
NCT06149663Longboard Pharmaceuticals
Available
Not Applicable
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 MutationAdvanced Non-small Cell Lung CancerCancer
NCT06761976Bayer
Available
Not Applicable
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple MyelomaMultiple Myeloma
NCT05346835Janssen Scientific Affairs, LLC